TRANSLUCENCE BIOSYSTEMS, INC.

Medtech · Private

3D brain imaging and analysis platform with machine learning-based vasculature subtraction for measuring antibody drug penetration in brain tissue

Grants
$5.4M
7 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
7
2 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Rapid Evaluation of Neuronal Activity in the Intact Whole-Brain at Single Cell Resolution$224,998
Federal grantDepartment of Health and Human Services · Phase I · Brain-wide quantitative mapping of microglia activation$449,956
Federal grantDepartment of Health and Human Services · Phase II · Rapid Evaluation of Neuronal Activity in the Intact Whole Brain at Single Cell Resolution$1,373,193
Federal grantDepartment of Health and Human Services · Phase I · Clearbot: a system for fully automated, high-throughput tissue clearing and immunostaining$459,655
Federal grantDepartment of Health and Human Services · Phase II · Rapid Evaluation of Neuronal Activity in the Intact Whole Brain at Single Cell Resolution$1,103,854
Federal grantDepartment of Health and Human Services · Phase II · Rapid Evaluation of Neuronal Activity in the Intact Whole Brain at Single Cell Resolution$400,492
Federal grantDepartment of Health and Human Services · Phase II · Brain-Wide Quantification of Blood-Brain Barrier Penetrating Antibody Therapeutics$1,400,651
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2200DOTS Devices——
2201OXYLO, INC.——
2202HELIX ACOUSTICS, LLC——
2203TRANSLUCENCE BIOSYSTEMS, INC.——
2204NanoSoft, LLC——
2205POLARITYTE MD, INC.——
2206CICADEA BIOTECH, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 7

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.